Literature DB >> 25975437

Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.

Manish D Sinha1, Charles Turner, Caroline J Booth, Simon Waller, Pernille Rasmussen, David J A Goldsmith, John M Simpson.   

Abstract

BACKGROUND: The aim of this study was to evaluate the association of serum intact fibroblast growth factor 23 (FGF23) concentrations with indexed left ventricular mass in children with non-dialysis stages 3-5 of chronic kidney disease (CKD).
METHODS: The study cohort comprised 83 children (51 boys; mean age 12.1 ± 3.2 years) with a mean estimated glomerular filtration rate (eGFR) of 32.3 ± 14.6 ml/min/1.73 m(2) who underwent clinic and ambulatory blood pressure measurement (ABPM), echocardiography and evaluation of biochemical markers of CKD-associated mineral bone disease.
RESULTS: The mean left ventricular mass index (LVMI) was 35.9 ± 8.5 g/m(2.7) (± standard deviation), with 30 (36.1 %) children showing left ventricular hypertrophy (LVH), all eccentric, as defined using age-specific criteria. For all subjects, the mean FGF23 concentration was 142.2 ± 204.4 ng/l and the normalised distribution following log transformation was 1.94 ± 0.39. There was significant univariate correlation of LVMI with GFR, body mass index (BMI) z-score and calcium intake, but not with 24-h systolic ABPM z-score, log intact parathyroid hormone or log FGF23. On multivariate analysis following adjustment for confounders, only elemental calcium content (g/kg/day) estimated from prescribed calcium-based phosphate binder dose (β = 154.9, p < 0.001) and BMI z-score (β = 2.397, p = 0.003) maintained a significant positive relationship with LVMI (model r (2) = 0.225).
CONCLUSIONS: We observed no significant relationship of FGF23 with LVMI. Larger studies in children are needed to clarify the roles of calcium-containing phosphate binders and FGF23 with LV mass and their roles in the evolution of the development of adverse cardiovascular outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25975437     DOI: 10.1007/s00467-015-3125-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  49 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

Review 2.  Cardiovascular disease in children with chronic kidney disease.

Authors:  Mark M Mitsnefes
Journal:  J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 10.121

3.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

4.  Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease.

Authors:  Michael van Husen; Ann-Katrin Fischer; Anja Lehnhardt; Ilka Klaassen; Kristina Möller; Dirk-E Müller-Wiefel; Markus J Kemper
Journal:  Kidney Int       Date:  2010-04-21       Impact factor: 10.612

5.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

6.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

7.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

Review 8.  Phosphate binders in CKD: chalking out the differences.

Authors:  Lesley Rees; Rukshana C Shroff
Journal:  Pediatr Nephrol       Date:  2009-11-07       Impact factor: 3.714

9.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

10.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Authors:  Majd A I Mirza; Anders Larsson; Håkan Melhus; Lars Lind; Tobias E Larsson
Journal:  Atherosclerosis       Date:  2009-05-21       Impact factor: 5.162

View more
  8 in total

1.  Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis.

Authors:  Amir Ahmad Nassiri; Monir Sadat Hakemi; Reza Safar-Pour; Ali Ahmadi; Maryam Tohidi; Babak Sharif Kashani; Fatemeh Esfehani; Soudabeh Alatab
Journal:  J Transl Int Med       Date:  2016-09-23

Review 2.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

3.  FGF23 and Left Ventricular Hypertrophy in Children with CKD.

Authors:  Mark M Mitsnefes; Aisha Betoko; Michael F Schneider; Isidro B Salusky; Myles Selig Wolf; Harald Jüppner; Bradley A Warady; Susan L Furth; Anthony A Portale
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-12       Impact factor: 8.237

Review 4.  The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.

Authors:  Alexander Grabner; Christian Faul
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

5.  The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.

Authors:  Ylva Tranæus Lindblad; Hannes Olauson; Georgios Vavilis; Ulf Hammar; Maria Herthelius; Jonas Axelsson; Peter Bárány
Journal:  Pediatr Nephrol       Date:  2017-08-09       Impact factor: 3.714

6.  Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study.

Authors:  Markus P Schneider; Johannes B Scheppach; Ulrike Raff; Sebastian Toncar; Christian Ritter; Thorsten Klink; Stefan Störk; Christoph Wanner; Georg Schlieper; Turgay Saritas; Sebastian D Reinartz; Jürgen Floege; Nele Friedrich; Rolf Janka; Michael Uder; Roland E Schmieder; Kai-Uwe Eckardt
Journal:  Kidney Int Rep       Date:  2018-10-11

7.  Left-ventricular diastolic dysfunction in Korean children with chronic kidney disease: data from the KNOW-Ped CKD study.

Authors:  Jeong Yeon Kim; Yeonhee Lee; Hee Gyung Kang; Il-Soo Ha; Hae Il Cheong; Hyun Jin Choi; Kyoung Hee Han; Seong Heon Kim; Min Hyun Cho; Jae Il Shin; Joo Hoon Lee; Young Seo Park; Heeyeon Cho
Journal:  BMC Nephrol       Date:  2020-12-09       Impact factor: 2.388

Review 8.  Physiological markers and multimorbidity: A systematic review.

Authors:  Gustavo Dias Ferreira; José Augusto Simões; Chamara Senaratna; Sanghamitra Pati; Pierre Fernando Timm; Sandro Rodrigues Batista; Bruno Pereira Nunes
Journal:  J Comorb       Date:  2018-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.